Rabies pre-exposure prophylaxis elicits long-lasting immunity in humans
| Autor: | Kevin E. Brown, Lorraine M. McElhinney, Trudy Goddard, Anthony R. Fooks, Hooman Goharriz, Karen L. Mansfield, Nick Andrews |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male Time Factors Endemic Diseases Injections Intradermal Rabies 030231 tropical medicine Immunization Secondary Antibodies Viral Cohort Studies 03 medical and health sciences Pre-exposure prophylaxis Sex Factors 0302 clinical medicine Immunity Humans Medicine 030212 general & internal medicine Vaccine Potency Immunization Schedule Travel Booster (rocketry) General Veterinary General Immunology and Microbiology biology business.industry Public Health Environmental and Occupational Health medicine.disease Antibodies Neutralizing Vaccination Titer Infectious Diseases Rabies Vaccines Immunology Cohort biology.protein Molecular Medicine Female Pre-Exposure Prophylaxis Antibody business |
| Zdroj: | Vaccine. 34:5959-5967 |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2016.09.058 |
| Popis: | Despite the availability of safe and effective human vaccines, rabies remains a global threat, with an estimated 60,000 human deaths annually attributed to rabies. Pre-exposure prophylaxis against rabies infection is recommended for travelers to countries where rabies is endemic, and also for those with a higher risk of exposure. In this study, the rabies-specific neutralising antibody responses in a cohort of rabies-vaccinated recipients over a period of twenty years have been assessed. In particular, the antibody response to primary vaccinations and boosters, and the waning of antibody post primary vaccination and post booster were investigated. The significance of gender, age at vaccination, vaccine manufacturer and vaccination intervals were also evaluated. These data confirm that rabies vaccination can elicit a neutralising antibody response that can remain at detectable levels for a number of years, without additional booster vaccinations. The antibody response following both primary vaccination and booster was significantly influenced by the gender of the subject (p=0.002 and 0.03 respectively), with supportive data that suggests an effect by the make of vaccine administered following primary vaccination, with significantly higher VNA titres observed for one vaccine manufactured prior to 2006 (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect